NEW YORK--(BUSINESS WIRE)--OneMedPlace announced today that two panel discussions at OneMedForum NY 2011 will discuss Regulatory and Reimbursement Issues and Building Sales and Distribution. The 2nd annual Trans-Atlantic conference has also added members to its advisory board and a second group of lesser known companies with remarkable growth potential.
The morning panel will discuss Regulatory and Reimbursement Issues. Increasingly, companies are launching in Europe while waiting for approval in the United States. This session will compare and contrast a CE Mark for Europe and a 510K in the United States and explore the merits of this strategy in terms of creating capital efficiency. The afternoon panel, Building a Sales and Distribution Organization, will examine and provide an understanding on innovative strategies to enter both the US market and the European Market. It will compare and contrast approaches to building sales organizations on both sides of the Atlantic.
Recently added presenting companies include: Provectus Pharmaceuticals develops a novel drug that selectively targets and destroys cancer cells without harming surrounding healthy tissue; ECI Biotech develops sensors for rapid infection determination at the point-of-care; BMEYE develops a unique non invasive blood pressure and cardiac output monitor; Bio-Path Holdings offers unique drug delivery technology, with initial focus on the treatment of cancer; Adherex Technologies develops novel drug adjuncts that maximize the therapeutic effect of currently used cancer drugs; Rubigo Therapeutics focuses on a combination product to deliver an immune response modifying drug that enables improved control and delivery of the therapeutic molecule; Advanced Cardiac Therapeutics specializes in advanced irrigated cardiac catheter ablation systems; Histogenics Inc. develops tissue regeneration technology for cartilage repair; Phytoceuticals develops a natural wound healing spray; IntelliCell BioSciences is an emerging leader in regenerative medicine and the use of adipose derived stem cell processes; Medicasafe develops technologies for medication compliance and adherence; Rib-X Pharmaceuticals develops innovative antibiotics for Serious Drug Resistant Infections; MacuCLEAR develops a novel treatment for age related macular degeneration; Small Bone Innovations is the first company to develop implants purely for small bones and joints; Threshold Pharmaceuticals develops small molecule therapeutics to treat cancer.
The Advisory Board to the OneMedForum has significantly contributed to identifying these innovative companies from around the world. “We are pleased with the support of our advisory board, which includes some of the leading investors from the UK, France, Germany, Switzerland, and Italy,” said Brett Johnson, Founder of OneMedPlace and conference co-chair. “The broad scope of global expertise lends exceptional insight to the conference,” Johnson added.
Recent additions to the Advisory Board include: Peter Leonardi, Ph.D. of Five Prime Advisors; Geeta Vemuri, Ph.D, MBA, Partner at Quaker BioVentures and former Analyst covering the healthcare sector; Walter Lin,M.D, MBA of Ascension Health Ventures and Board Certified internist primarily focused on investments in the medical device sector; Michael Devries, MBA, Managing Director with EDF Ventures; and Hervé de Kergrohen, M.D., CEO of Glenbrook Ventures, a Swiss based investment advisory firm. For a complete list of advisors, please visit www.onemedplace.com/forum.
If you are interested in applying to present or attend, please visit: http://www.onemedplace.com/forum/registration.
OneMedPlace is a virtual community that connects emerging companies seeking capital, distribution, and visibility with investors and strategic partners looking for health and medical innovations to invest in, acquire, license, distribute, purchase or utilize.
Founded in 2008, OneMedForum events are held biannually in San Francisco in January and in New York in June. They are designed to create a communications platform for emerging companies to connect with strategic partners and investors.